The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer

BJU International

Volumn 102, Issue 1, 2008, Pages 125-129

  Ramsey, Sara ^a   Aitchison, Michael ^a   Graham, John ^b   McMillan, Donald C ^c  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Albumin; C reactive protein; Cancer specific survival; Grade; Immunotherapy; Interleukin; Renal cancer; T lymphocytes; Tumour stage

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; FLUOROURACIL; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; KIDNEY CANCER; LABORATORY TEST; LEUKOCYTE COUNT; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

ALBUMINS; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T-LYMPHOCYTES;

EID: 44849126960     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07466.x     Document Type: Article

References (26)

1. Cancer Research UK. Available at: http://info.cancerresearchuk.org/ cancerstats/types/kidney/survival/?a=5441. Accessed November 2007
2. Steineck G, Strander H, Carbin BE et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 1990 29 : 155 62
3. Kreigmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995 45 : 758 62
4. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999 353 : 14 7
5. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999 17 : 2859 67
6. Blay JY, Negrier S, Combaret V et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992 52 : 3317 22
7. Bromwich E, McMillan DC, Lamb GWA et al. The systemic inflammatory response, performance status and survival in patients undergoing alpha interferon therapy for advanced renal cancer. Br J Cancer 2004 91 : 1236 8
8. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999 17 : 2530 40
9. Ramsey S, Lamb GW, Aitchison M et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007 109 : 205 12
10. Maccio A, Lai P, Santona MC et al. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998 69 : 248 52
11. Canna K, McArdle PA, McMillan DC et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005 92 : 651 4
12. Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. NEJM 1999 340 : 448 54
13. Negrier S, Perol D, Menetrier-Caux A et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma; prognostic value of interleukin-6: from the Groupe Francais d'Immunotherapie. J Clin Oncol 2004 22 : 2371 8
14. Atzpodien J, Kirchner H, Illiger HJ et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001 85 : 1130 6
15. Sobin L, Wittekind C. International Union Against Cancer. (UICC) TNM Classification of Malignant Tumors, 5th edn. New York : Wiley-Liss, 1997 : 180 2
16. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982 6 : 655 63
17. Forrest LM, McMillan DC, McArdle CS et al. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004 90 : 1704 6
18. Forrest LM, McMillan DC, McArdle CS et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003 89 : 1028 30
19. Maltoni M, Caraceni A, Brunelli C et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005 23 : 6240 8
20. Steensberg A, Fischer CP, Keller C et al. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003 285 : E433 7
21. Hernberg M, Muhonen T, Pyrhonen S. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma? Ann Oncol 1997 8 : 71 7
22. Gohring B, Riemann D, Rebmann U et al. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU. Urol Res 1996 24 : 297 303
23. Hernberg M. Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. Med Oncol 1999 16 : 145 53
24. Favrot MC, Combaret V, Negrier S et al. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod 1990 9 : 167 77
25. Donskov F, Bennedsgaard KM, Von Der Maase H et al. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 2002 87 : 194 201
26. Wittke F, Hoffmann R, Buer J et al. Interleukin 10 (IL-10). an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer 1990 79 : 1182 4